Get started
Author

Tienan Yi

Observed name: Tie-Nan Yi
ORCID: 0009-0008-8678-4841
Observed ORCID: 0009-0008-8678-4841
OpenAlex ID: A5109579456
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial
2024 · HARMONi-A Study Investigators, Wenfeng Fang, et al. · JAMA · 257
PDF
Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial
2024 · Ying Cheng, Jianhua Chen, et al. · Nature Medicine · 164
PDF
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
2024 · Zefei Jiang, Quchang Ouyang, et al. · Nature Medicine · 157
Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer: The Phase 3 EXTENTORCH Randomized Clinical Trial
2024 · Ying Cheng, Wei Zhang, et al. · JAMA Oncology · 85
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials
2025 · Shen Zhao, Ying Cheng, et al. · Nature Medicine · 76
Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b Study
2022 · Yuankai Shi, Shiman Wu, et al. · Journal of Thoracic Oncology · 35
PDF
Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study
2022 · Shun Lu, Yiping Zhang, et al. · Journal of Thoracic Oncology · 30
PDF
Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study
2025 · Yuankai Shi, Yanzhen Guo, et al. · The Lancet Respiratory Medicine · 26
Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
2026 · Anwen Xiong, Wenxiu Yao, et al. · The Lancet · 20
A multicenter, randomized, double-blind, placebo-controlled phase 3 study of Socazolimab or placebo combined with carboplatin and etoposide in the first-line treatment of extensive-stage small cell lung cancer
2025 · Zhiwei Chen, Jianhua Chen, et al. · Signal Transduction and Targeted Therapy · 20
PDF
Intrapleural infusion of tumor cell-derived microparticles packaging methotrexate or saline combined with pemetrexed-cisplatin chemotherapy for the treatment of malignant pleural effusion in advanced non-squamous non-small cell lung cancer: A double-blind, randomized, placebo-controlled study
2022 · Xiaorong Dong, Yu Huang, et al. · Frontiers in Immunology · 20
The relationship among human papilloma virus infection, survivin, and p53 gene in lung squamous carcinoma tissue
2010 · Yue-Hua Wang, De-jie Chen, et al. · Saudi Medical Journal · 16
A phase II trial to evaluate the safety and efficacy of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, as a monotherapy in patients with advanced NSCLC.
2025 · Lin Wu, Jun Yao, et al. · Journal of Clinical Oncology · 14
PDF
MicroRNA-130a regulates cell malignancy by targeting RECK in chronic myeloid leukemia.
2016 · Quan Li, Yaohui Wu, et al. · PubMed · 14
Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial
2026 · HARMONi-A Study Investigators, Wenfeng Fang, et al. · JAMA · 13
Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial
2026 · Hua Zhong, Jing Wang, et al. · The Lancet Oncology · 10
Randomized, Phase III Trial of Mixed Formulation of Fosrolapitant and Palonosetron (HR20013) in Preventing Cisplatin-Based Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: PROFIT
2024 · Huaqiang Zhou, Yuanyuan Zhao, et al. · Journal of Clinical Oncology · 10
CAMPASS: Benmelstobart in combination with anlotinib vs pembrolizumab in the first-line treatment of advanced non-small cell lung cancer (aNSCLC)—A randomized, single-blind, multicenter phase 3 study.
2025 · Baohui Han, Kai Li, et al. · Journal of Clinical Oncology · 9
Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
2025 · Ying Cheng, Jie Wang, et al. · Clinical Cancer Research · 9
Phase I/II combination study of tifcemalimab with toripalimab in patients with refractory extensive stage small cell lung cancer (ES-SCLC).
2023 · Ying Cheng, Jie Wang, et al. · Journal of Clinical Oncology · 9
PDF
A phase 2 dose expansion study of ZG006, a trispecific T cell engager targeting CD3/DLL3/DLL3, as monotherapy in patients with advanced small cell lung cancer.
2025 · Xinghao Ai, Yun Yan Zhang, et al. · Journal of Clinical Oncology · 8
PDF
Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation: A pooled analysis of two clinical studies
2023 · Sheng Yang, Shiman Wu, et al. · Lung Cancer · 7
PDF
Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trial
2024 · Shun Lu, Yiping Zhang, et al. · Lung Cancer · 6
Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial
2026 · Herui Yao, Qingyuan Zhang, et al. · The Lancet Oncology · 5
Updated results from a phase 2 trial of SSGJ-707 (PF-08634404), a PD-1/VEGF bispecific antibody, as monotherapy in patients with advanced non-small cell lung cancer (NSCLC).
2026 · Lin Wu, Jun Yao, et al. · Journal of Clinical Oncology · 5
Works count: 72
Citation count: 988
H-index: 14
I10-index: 17
Year
Topic
Type